NCT02795520View on ClinicalTrials.gov

Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

May 31, 2021

Study Completion Date

September 30, 2021

Conditions
AMLAdvanced MDSALLAdvanced CMLAdvanced MPNs
Interventions
DRUG

OTS167IV

Trial Locations (2)

10065

Weill Cornell Medicine, New York

60637

University of Chicago, Chicago

Sponsors
All Listed Sponsors
lead

OncoTherapy Science, Inc.

INDUSTRY

NCT02795520 - Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter